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We evaluated children (15-months old and older) with recurrent upper respiratory tract infections and nor-
mal levels of immunoglobulins in serum for specific polysaccharide immunodeficiency using an enzyme-linked
immunosorbent assay method. Results showed that of 12 patients vaccinated with Act-HIB vaccine, one did not
develop specific antibodies to Haemophilus influenzae type b, demonstrating that such immunodeficiency is
present in Costa Rican children.
Infections of the upper respiratory tract in children are a
main reason for visits with pediatricians, and these patients
show a high morbidity rate. In some of these children, such
infections have a recurrent pattern (2). At present, there are
no uniform criteria to define recurrent infection, but several
repeated infections in a year should be considered to constitute
recurrent infection (9).
In recent years, an immunodeficiency characterized by the
selective inability to respond to polysaccharide antigens has
been described (5, 6). This defect is suspected in patients who
suffer from recurrent upper respiratory tract infections, espe-
cially those caused encapsulated bacteria, and who have nor-
mal serum immunoglobulin levels (9, 12). The absence of an-
tibody response to bacterial polysaccharides, in the presence of
a normal response to protein antigens, is a common charac-
teristic of these patients (1).
Different laboratory methods that determine specific anti-
bodies toward bacterial polysaccharide antigens have been de-
veloped (8, 13). However, immunoenzymatic techniques such
as enzyme-linked immunosorbent assay (ELISA) are used
most often due to their simplicity and sensitivity. As an alter-
native, special plastic surfaces for the covalent attachment of
polysaccharides, or the conjugation of polysaccharides to pro-
tein carriers, have been utilized (10, 13).
In this investigation three ELISA methods were standard-
ized to detect children with polysaccharide-specific immuno-
deficiency in a population of patients with recurrent respira-
tory tract infections.
Population. All children older than 15 months of age with
recurrent respiratory tract infections who had been referred to
the Immunology Outpatient Clinic at National Children’s Hos-
pital in San Jose´, Costa Rica, between October 1998 and June
1999 were included. All patients had normal serum immuno-
globulin concentrations. Recurrent infection was defined as
follows: (i) recurrent otitis, three episodes in 6 months or four
episodes in 1 year; (ii) sinusitis and/or recurrent bronchopneu-
monia, two episodes in 6 months or three episodes in 1 year or;
(iii) recurrent rhinopharyngitis, four episodes in 6 months or
eight episodes in 1 year. Children were excluded from the
study if they had a primary immunodeficiency, a chronic pul-
monary illness, or a structural congenital malformation. Once
the patients were identified, parents were asked for written
consent. The study was approved by the hospital’s investigation
committee.
Two blood samples were collected from each patient. The
first sample was collected before the application of the Act-
HIB vaccine (Pasteur-Me´rieux), and the second was collected
4 to 6 weeks later. Both serum samples, pre- and postvaccina-
tion, were stored at 20°C until analysis.
ELISA. Haemophilus influenzae type b (Hib) vaccine conju-
gated to diphtheria toxoid (Hib TITER; Lederle Laboratories)
was used as an antigen to coat ELISA plates (Immulon 2;
Dynatech Laboratories). To determine the optimal minimum
concentration of antigen for coating, the following concentra-
tions were tested: 1.0, 0.5, 0.25, 0.12, 0.06, and 0.03 g/100
l/well. The antigen was diluted in coating buffer (Tris, 0.05 M;
NaCl, 0.15 M; pH 9.0) and adsorbed onto the wells of micro-
titer plates during incubation at room temperature overnight.
After rinsing the plates five times with this buffer, the wells
were blocked with 1% bovine serum albumin (BSA) in FALC
buffer (Tris, 0.05 M; NaCl, 0.15 M; ZnCl2, 20 M; MgCl2, 1
mM; pH 7.4) for 30 min. Then, the plates were decanted and
different dilutions (100 l/well) of international reference anti-
Hib sera (70 g of anti-Hib/ml, lot 1983; Food and Drug Ad-
ministration, Washington, D.C.) starting at 1:50 were added.
Dilutions were prepared in FALC buffer containing 1% BSA.
After 2 h at room temperature, the plates were rinsed five
times with FALC buffer; goat anti-human immunoglobulin G
(IgG)–alkaline phosphatase, diluted 1:5,000 in FALC buffer–
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1% BSA was added; and the plates were incubated for 2 h at
room temperature. After washing, 100 l of a 1-mg/ml con-
centration of p-nitrophenyl phosphate in substrate buffer was
added to all wells. Absorbance readings at 410 nm were deter-
mined using a Dynatech MR5000 microplate reader. All sam-
ples were assayed in triplicate.
Pre- and postvaccination samples were analyzed at four dif-
ferent dilutions, with threefold serial dilutions starting at 1:100.
Dilutions were prepared in FALC buffer–1% BSA. The back-
ground was established with wells without antigen, processed
identically to a patient sera.
Hib vaccine (0.05 g) conjugated to diphtheria toxoid was
selected at an optimal concentration for coating microtiter
plates, and a 1:300 dilution was selected as optimal for IgG
antibody determinations.
An antibody response to polyribosyl ribitol phosphate (PRP)
was considered positive if absorbance readings of the postvac-
cination serum sample were at least double the absorbance
readings of the prevaccination sample when absorbance read-
ings were higher than 0.1. For statistical comparisons, the Stu-
dent t test was utilized. A P value of 0.05 was considered
statistically significant.
During the 9-month study period, 12 patients were included,
8 male and 4 female, with ages between 15 and 44 months
(median, 22 months). One patient had received three previous
doses of Hib vaccine, and another one had been vaccinated
twice. The rest of the patients had never been vaccinated
against Hib.
Patient analysis. In this investigation, 12 children were eval-
uated. One patient did not show an IgG antibody response
after vaccination (Fig. 1). Anti-diphtheria toxoid IgG antibody
analyses demonstrated that postvaccine levels decreased or
remained similar to prevaccine levels in 11 patients. In the one
remaining patient, postvaccine antibody levels increased slight-
ly (Fig. 2). All patients produced anti-tetanus toxoid IgG an-
tibodies in high concentrations after immunization (Fig. 3).
This investigation evaluated polysaccharide-specific immu-
nodeficiency in children showing recurrent upper respiratory
tract infection and normal serum immunoglobulin concentra-
tions. We evaluated 12 patients because to meet the criteria for
selection for the study population, children needed to receive
a booster vaccine and be at least 15 months old.
This population is not uniform because, at the time the study
was done, the Costa Rican Social Security System did not
provide Hib vaccination.
The inconvenience of using ELISA methods in the detection
of antipolysaccharide antibodies lies in the difficulties encoun-
tered when these antigens are absorbed to the solid phase.
Conjugation techniques sometimes result in alterations of
the antigen’s native structure (3–5). We utilized a commercial
preparation of PRP conjugated to a carrier protein, which has
been used for vaccination and which has shown good immu-
nogenicity (9). This antigen was efficient in detecting anti-PRP
IgG in children receiving an H. influenzae vaccine that was
based on PRP conjugated to a different carrier protein. In spite
of the small number of patients, it was proven that a specific
FIG. 1. Levels of anti-PRP IgG antibodies to Hib pre- and postvaccination, in serum of children with recurrent respiratory infection and normal
serum immunoglobulin concentrations. Patient 1 had three doses and patient 4 had two doses of Act-HIB vaccine, prior to the study. Asterisks
indicate significant (P  0.05) increases from prevaccination levels.
FIG. 2. Levels of anti-diphtheria toxoid IgG antibodies, pre- and
postvaccination, in serum of children with recurrent respiratory infec-
tion and normal serum immunoglobulin concentrations, Asterisk indi-
cates a significant (P  0.05) increase from prevaccination level.
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immunodeficiency to polysaccharides of bacterial origin, de-
tected by the absence of antibodies to polysaccharide antigens
of bacterial origin, is a pathology present in Costa Rican chil-
dren; thus, it may be a cause of recurrent infections of the
upper respiratory tract in this population. The low percentage
of detection of this specific immunodeficiency to the PRP
polysaccharide of Hib is similar to that observed in countries
such as Spain (7) and Brazil (11).
In addition, the present study verified that the tetanus pro-
tein can be used as an indicator of an adequate immune re-
sponse to T-dependent antigens (1). This is because the min-
imal concentration present in the Hib TITER vaccine was
sufficient to stimulate the immune system of the evaluated
children without the need for vaccinating them separately with
tetanus toxoid.
We did not check the patients’ IgG subtypes before doing
these ELISAs because a method was not available and clinical
history does not coincide with children having an IgG subclass
deficiency.
Since the causes of the specific immunodeficiency to the
PRP polysaccharide of Hib are still unknown, we recommend
that this study be repeated when these patients are more than
6 years old, in order to determine whether the cause of this
immunodeficiency is retardation in the maturation of the im-
mune system to polysaccharide antigens.
We thank the German Academic Exchange Service (DAAD) for
supporting this study and Carl Frasch (Food and Drug Administration)
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FIG. 3. Levels of anti-tetanus toxoid IgG antibodies, pre- and post-
vaccination, in serum of children with recurrent respiratory infection
and normal serum immunoglobulin concentrations. Asterisks indicate
significant (P  0.05) increases from prevaccination levels.
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